C4 Therapeutics, Inc. Temporary Equity, Liquidation Preference
C4 Therapeutics, Inc. (CCCC) had Temporary Equity, Liquidation Preference of $256.52 million as of 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Balance Sheet › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2021-03-11
- 2020-09-30: Temporary Equity, Liquidation Preference $256.52M.
- 2019-12-31: Temporary Equity, Liquidation Preference $111.00M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2020-09-30 | $256.52M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $111.00M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |